JP2001010970A - Antineoplastic fraction from agaricus blazei murill - Google Patents

Antineoplastic fraction from agaricus blazei murill

Info

Publication number
JP2001010970A
JP2001010970A JP11188112A JP18811299A JP2001010970A JP 2001010970 A JP2001010970 A JP 2001010970A JP 11188112 A JP11188112 A JP 11188112A JP 18811299 A JP18811299 A JP 18811299A JP 2001010970 A JP2001010970 A JP 2001010970A
Authority
JP
Japan
Prior art keywords
supernatant
precipitate
hot water
fraction
health food
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP11188112A
Other languages
Japanese (ja)
Other versions
JP4480204B2 (en
Inventor
Tomihisa Ota
富久 太田
Takuma Sasaki
琢磨 佐々木
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SUNDORY KK
Kyowa Engineering Co Ltd
Original Assignee
SUNDORY KK
Kyowa Engineering Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SUNDORY KK, Kyowa Engineering Co Ltd filed Critical SUNDORY KK
Priority to JP18811299A priority Critical patent/JP4480204B2/en
Publication of JP2001010970A publication Critical patent/JP2001010970A/en
Application granted granted Critical
Publication of JP4480204B2 publication Critical patent/JP4480204B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

PROBLEM TO BE SOLVED: To obtain a novel medicine or health food which exhibits excellent pharmacological activity and can easily be absorbed by digestive tracts. SOLUTION: This antineoplastic agent or health food includes a chromatography main elution fraction of molecular weight 100-2,000 obtained by the process for extracting fruit bodies of Agaricus blazei Murill with hot water, the process for dialyzing the extract and the process for treating the dialyzed outer solution by chromatography as an active ingredient. The antineoplastic agent or health food is obtained by including a dialyzed outer solution, which is obtained by the process for extracting the fruit bodies with hot water, the process for mixing the extract with ethanol and centrifuging the mixture to divide into a precipitate and a supernatant, the process for mixing the supernatant with ethanol and centrifuging the mixture to divide into a precipitate and a supernatant and then the process for dissolving the precipitate into distilled water to dialyze, as an active ingredient.

Description

【発明の詳細な説明】DETAILED DESCRIPTION OF THE INVENTION

【0001】[0001]

【発明の属する技術分野】本発明はカワリハラタケの子
実体を熱水抽出処理して得られる比較的低分子量の物質
を含有する抗腫瘍剤もしくは健康食品に関する。
BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to an antitumor agent or health food containing a substance having a relatively low molecular weight, which is obtained by subjecting fruiting bodies of Kawariharatake to hot water extraction.

【0002】[0002]

【従来の技術】カワリハラタケは抗腫瘍活性を有するこ
とが知られており、その粉末あるいは種々の抽出物が健
康食品として経口的に利用されている。特にカワリハラ
タケ由来の蛋白多糖体等高分子物質については多数報告
されている。
2. Description of the Related Art Kawariharatake is known to have antitumor activity, and its powder or various extracts are used orally as health foods. In particular, many polymer substances such as protein polysaccharides derived from Kawariharatake have been reported.

【0003】[0003]

【発明が解決しようとする課題】蛋白多糖体等高分子物
質については、一般的には必ずしも消化管からの吸収が
良いとはいえない。より低分子物質で優れた薬理活性を
有する物質、特に経口的投与が可能な物質は医薬品とし
ても健康食品としても常に求められている。
Generally, high-molecular substances such as protein polysaccharides cannot always be said to have good absorption from the digestive tract. Substances having lower molecular weight and excellent pharmacological activity, especially substances which can be orally administered, are always required as pharmaceuticals and health foods.

【0004】[0004]

【課題を解決するための手段】抗腫瘍活性成分探索の一
環として、マウスへの経口投与に基づく活性試験を検討
してきた。その結果、ハラタケ属担子菌 Agaricus blaz
ei Murill(カワリハラタケ、協和アガリクス茸)の比
較的低分子の熱水抽出画分に抗腫瘍活性を認めたことか
ら、活性成分の分画を行い本発明に至った。
Means for Solving the Problems As part of the search for an antitumor active ingredient, an activity test based on oral administration to mice has been studied. As a result, Agaricus blaz
Since the antitumor activity was recognized in the relatively low-molecular-weight hot-water-extracted fraction of ei Murill (Kawariharatake, Kyowa agaricus mushroom), the present invention was carried out by fractionating the active ingredient.

【0005】本発明はカワリハラタケの子実体を熱水抽
出する工程、抽出物を透析処理する工程および透析外液
をクロマトグラフィー処理する工程によって得られる分
子量100〜2000のクロマトグラフィー主溶出画分
を有効成分とする抗腫瘍剤もしくは健康食品に関する。
[0005] The present invention is effective for a main elution fraction of chromatography having a molecular weight of 100 to 2,000 obtained by a step of extracting a fruit body of Kawariharatake with hot water, a step of dialysis of the extract, and a step of chromatography of an outer dialysate. It relates to an antitumor agent or health food as a component.

【0006】本発明はまた、カワリハラタケの子実体を
熱水抽出する工程、抽出物にエタノールを加えて混合
し、混合物を遠心分離して沈殿と上澄液に分ける工程、
上澄液にエタノールを加えて混合し、混合物を遠心分離
して沈殿と上澄液に分ける工程および沈殿物を蒸留水に
溶解して透析処理する工程によって得られる透析外液を
有効成分とする抗腫瘍剤もしくは健康食品に関する。
[0006] The present invention also provides a step of extracting the fruit body of Kawariharatake with hot water, a step of adding ethanol to the extract and mixing the mixture, and centrifuging the mixture to separate a precipitate and a supernatant.
Ethanol is added to the supernatant and mixed, and the mixture is centrifuged to separate into a precipitate and a supernatant, and the precipitate is dissolved in distilled water and the dialysis process is performed, and the outer dialysis solution obtained is used as an active ingredient. Related to antitumor agents or health foods.

【0007】[0007]

【発明の実施の形態】以下に本発明の抗腫瘍活性成分の
製法について説明する。本発明で用いられるカワリハラ
タケの子実体は天然物でも人工培養物でも用いうるが、
市販されている乾燥物も便利に利用できる。カワリハラ
タケの乾燥子実体に5から10倍の水を加えて1〜3時
間加熱還流することによって行われる。熱水抽出は熱水
抽出残さについてもさらに加熱還流を繰り返して行われ
る。かくして得られる熱水抽出液を凍結乾燥して、乾燥
物(以下乾燥物Aという)を得る。この乾燥物に5〜20
倍の水を加え、透析チューブに入れ数倍の蒸留水で10
〜15時間透析し、透析外液を凍結乾燥することによっ
て抗腫瘍活性を有する乾燥物(以下乾燥物Cという)を
得ることができる。
DESCRIPTION OF THE PREFERRED EMBODIMENTS Hereinafter, a method for producing an antitumor active ingredient of the present invention will be described. The fruit body of Kawariharatake used in the present invention may be used in natural products or artificial cultures,
Commercially available dried products can also be conveniently used. It is carried out by adding 5 to 10 times water to the dried fruit body of Kawariharatake and heating and refluxing for 1 to 3 hours. Hot water extraction is performed by repeating heating and refluxing of the hot water extraction residue. The hot water extract thus obtained is freeze-dried to obtain a dried product (hereinafter referred to as dried product A). 5 to 20
Add water twice, place in dialysis tubing, and add 10 times with distilled water.
A dried product having an antitumor activity (hereinafter referred to as a dried product C) can be obtained by dialysis for up to 15 hours and freeze-drying the outer dialysate.

【0008】次に、透析内液についてもさらに流水中で
20〜40時間透析し、蒸留水で2回、各数時間透析し
た後透析内液を凍結乾燥することによって抗腫瘍活性を
有する乾燥物(以下乾燥物Bという)を得ることができ
る。得られた乾燥物Cを約10倍の蒸留水に溶解し、蒸
留水を流出溶媒としてクロマトグラフィーを行い、20
mLずつ分取し、多くの画分を得る。得られた画分の中
程の主溶出画分で、ゲルろ過法によって分子量100〜
2000の画分が本発明の高い腫瘍阻害活性を示す画分
である。これらの画分はさらにODSを用いる逆相クロマ
トグラフィー、DEAE-TOYOPEARL650を用いるイオン交換
クロマトグラフィーなどに付して分析すると、アルギニ
ン、リジン、マンニトールの他、数種の成分を含んでい
ることが確認されている。
Next, the inner dialysis solution is further dialyzed for 20 to 40 hours in running water, dialyzed twice with distilled water for several hours each, and then lyophilized to obtain a dried product having antitumor activity. (Hereinafter referred to as dried product B). The obtained dried product C was dissolved in about 10 times the volume of distilled water, and chromatography was carried out using distilled water as an eluent.
Separate by mL to obtain many fractions. The main eluted fraction in the middle of the obtained fraction, having a molecular weight of 100 to
2000 fractions are the fractions showing high tumor inhibitory activity of the present invention. Analysis of these fractions by reverse phase chromatography using ODS, ion exchange chromatography using DEAE-TOYOPEARL650, etc. confirmed that they contained several components in addition to arginine, lysine and mannitol. Have been.

【0009】また、前記方法で得られる熱水抽出液にエ
タノールを等量加えて混合し、遠心分離処理して沈殿と
上澄液に分ける。得られる上澄液にさらにその1から3
倍量のエタノールを加えて混合し、遠心分離処理して得
られる沈殿を蒸留水に溶解し、この溶液を透析処理して
得られる透析外液は低分子画分で本発明の高い腫瘍阻害
活性を示す画分である。かくして得られる高い腫瘍阻害
活性を示す画分はそのままあるいは経口医薬製剤の製造
に用いられる種々の賦形剤と共に医薬製剤を製造するこ
とができる。また、当該画分はそのままもしくは他の食
品と共に健康飲食品として利用することができる。
[0009] Further, an equal amount of ethanol is added to the hot water extract obtained by the above method, mixed and centrifuged to separate a precipitate and a supernatant. The obtained supernatant is further added with 1 to 3
A double volume of ethanol is added and mixed, the precipitate obtained by centrifugation is dissolved in distilled water, and the resulting dialysis solution obtained by dialysis of the solution is a low-molecular fraction, which is a high tumor-inhibiting activity of the present invention. Is a fraction showing The fraction having high tumor-inhibiting activity thus obtained can be used as a pharmaceutical preparation as it is or together with various excipients used in the production of oral pharmaceutical preparations. The fraction can be used as it is or as a health food or drink with other foods.

【0010】[0010]

【実施例】実施例1 Agaricus blazei Murill 300 g(協和アガリクス茸)に
蒸留水 2 Lを加え、2時間加熱還流を行った。これをろ
過してろ液(熱水抽出液)と残査とに分けた。残査には
再び蒸留水2 Lを加え、2 時間加熱還流して熱水抽出を
行い、ろ液を得た後、残査についてもう一度同様の熱水
抽出を行い、ろ液を合一した。合一したろ液(熱水抽出
液)は凍結乾燥し、乾燥物A153 g(51%)を得た。乾
燥物A50 gに蒸留水500 mL加え透析チユーブ(Spectra
/Por Membrane 50x31,8mm id x30 m, FE一0526−65)
に入れた。これを3 Lの蒸留水に対し、12時間透析をし
た。この透析外液を凍結乾燥して乾燥物C27g(53%)
を得た。透析内液についてはさらに流水中で30時間透析
し、その後蒸留水で2回(各4時間、合計8時間)透析し
た後、透析内液を凍結乾燥し、乾燥物B11 g(22%)を
得た。続いて、乾燥物C3 gを30 mLの蒸留水に溶かしTO
YOPEARL HW40C(40 mm id x 420 mm)を用いるクロマト
グラフィーを行った。流出溶媒はすべて蒸留水を用い
た。各フラクションについてそれぞれ20 mLずつ分取
し、画分1〜30を得た。それらのフラクションは薄層ク
ロマトグラフィーを参考にして以下の5群に分けた。重
量は次の通りであった。画分1〜11 (75 mg, 2.5%)、
画分12〜15 (920 mg, 30.7%)、画分16〜17 (1570 mg,
52.3%)、画分18〜19 (270 mg, 9%)、画分20〜28 (97 m
g, 3,2%)。 赤外線吸収スペクトル(IR)データは以下の通りであ
る。 画分16:IR(KBr)3390, 3325, 3285, 2940, 2920, 164
1, 1634, 1622, 1615, 1600,1595, 1405, 1394, 1084,
1020. 分子量(ゲルろ過法) 100〜2000
EXAMPLES Example 1 2 L of distilled water was added to 300 g of Agaricus blazei Murill (Kyowa agaricus mushroom), and the mixture was heated under reflux for 2 hours. This was filtered and separated into a filtrate (hot water extract) and a residue. To the residue, 2 L of distilled water was added again, and the mixture was heated under reflux for 2 hours to perform hot water extraction. After obtaining a filtrate, the residue was subjected to another similar hot water extraction, and the filtrates were combined. The combined filtrate (hot water extract) was freeze-dried to obtain 153 g (51%) of dried product A. Add 50 mL of distilled water to 50 g of dried product A and add dialysis tube (Spectra
/ Por Membrane 50x31,8mm id x30 m, FE 0526-65)
Put in. This was dialyzed against 3 L of distilled water for 12 hours. This outer dialysis solution is freeze-dried and dried matter C27g (53%)
I got The inner dialysis solution was further dialyzed in running water for 30 hours, then dialyzed twice with distilled water (4 hours each, 8 hours in total), and the inner dialysis solution was freeze-dried to obtain 11 g (22%) of dried product B (22%). Obtained. Subsequently, 3 g of the dried product C was dissolved in 30 mL of distilled water and TO
Chromatography was performed using YOPEARL HW40C (40 mm id x 420 mm). All effluent solvents used distilled water. Fractions 1 to 30 were obtained by fractionating 20 mL of each fraction. These fractions were divided into the following five groups with reference to thin layer chromatography. The weight was as follows. Fractions 1 to 11 (75 mg, 2.5%),
Fractions 12-15 (920 mg, 30.7%), Fractions 16-17 (1570 mg,
52.3%), fractions 18-19 (270 mg, 9%), fractions 20-28 (97 m
g, 3,2%). The infrared absorption spectrum (IR) data is as follows. Fraction 16: IR (KBr) 3390, 3325, 3285, 2940, 2920, 164
1, 1634, 1622, 1615, 1600,1595, 1405, 1394, 1084,
1020. Molecular weight (gel filtration method) 100-2000

【0011】アガリクス熱水抽出成分及び透析画分の抗
腫瘍性試験を下記により実施した。 1)投与サンプル 下記(A)〜(D)の 1〜10 mg/mL
濃度水溶液を用いた。 (A)アガリクス熱水抽出エキス(乾燥物A、熱水抽出
液の凍結乾燥品) (B)高分子画分(前記乾燥物B) (C)低分子画分(前記乾燥物C) (D)低分子画分(クロマトグラフ画分16) 2)動物として、ICR/JCL マウス (5週令 雌、6匹/
群) -- 6匹 x3群 x6種を用いた。 3)腫瘍細胞株: Sarcoma 180 細胞。37℃で継代培養し
た。 (方法) ICRマウスを用いるin vivo アッセイ(経口投与) 1)マウス片足の皮下に Sarcoma 180細胞を 2-5X10,00
0,000 cells/mouseの割合いで移植した。 2)1〜10日の間、薬剤の水溶液を経口投与した。薬
剤の濃度は1種類の薬剤につき 10 mg/mL とした。 3)5週間に渡って半週毎に腫瘍容積の観察を行い、最
終日に腫瘍塊を摘出し、重量を測定した。腫瘍容積は腫
瘍塊の長径及び短径から換算した。 (結果)投与サンプルの腫瘍阻害率は以下の通りであっ
た。 (A)68%、(B)65%、(C)71%、(D)8
3%
The antitumor test of the Agaricus hot water extract component and the dialyzed fraction was carried out as follows. 1) Administration sample 1 to 10 mg / mL of the following (A) to (D)
A concentrated aqueous solution was used. (A) Agaricus hot water extract (dry matter A, freeze-dried hot water extract) (B) High molecular fraction (dry matter B) (C) Low molecular fraction (dry matter C) (D ) Low molecular fraction (chromatographic fraction 16) 2) ICR / JCL mice (five-week-old female, 6 /
Group)-6 animals x 3 groups x 6 species were used. 3) Tumor cell line: Sarcoma 180 cells. The cells were subcultured at 37 ° C. (Method) In vivo assay using ICR mouse (oral administration) 1) 2-5X10,00 Sarcoma 180 cells subcutaneously under one foot of mouse
The transplant was performed at a rate of 0,000 cells / mouse. 2) An aqueous solution of the drug was orally administered for 1 to 10 days. The drug concentration was 10 mg / mL for each drug. 3) The tumor volume was observed every half week for 5 weeks, and the tumor mass was excised and weighed on the last day. The tumor volume was calculated from the major axis and minor axis of the tumor mass. (Results) The tumor inhibition rates of the administered samples were as follows. (A) 68%, (B) 65%, (C) 71%, (D) 8
3%

【0012】実施例2 実施例1と同様の熱水抽出を実施して、合一したろ液
(熱水抽出液)6Lを得た。このろ液を減圧濃縮して1L
とし、これにエタノール1Lを加えて混合し、遠心分離
して沈殿と上澄液を得た。この上澄液にさらにエタノー
ル3Lを加えて混合し、遠心分離して得られる沈殿を蒸
留水に溶解し、透析処理した。その透析外液について実
施例1と同様に腫瘍増殖阻害率を求めたところ86%で
あった。
Example 2 The same hot water extraction as in Example 1 was performed to obtain 6 L of a combined filtrate (hot water extract). The filtrate is concentrated under reduced pressure to 1 L
Then, 1 L of ethanol was added thereto, mixed, and centrifuged to obtain a precipitate and a supernatant. 3 L of ethanol was further added to the supernatant, mixed, and the precipitate obtained by centrifugation was dissolved in distilled water and dialyzed. The tumor growth inhibition rate of the external dialysate was determined in the same manner as in Example 1 and was found to be 86%.

【0013】[0013]

【発明の効果】本発明によりカワリハラタケを熱水抽出
することによって得られる抗腫瘍性画分を含有する抗腫
瘍剤ならびに健康食品が提供される。
Industrial Applicability According to the present invention, an antitumor agent and a health food containing an antitumor fraction obtained by extracting Kawariharatake with hot water are provided.

───────────────────────────────────────────────────── フロントページの続き (72)発明者 太田 富久 石川県金沢市平和町2−28−60 (72)発明者 佐々木 琢磨 石川県金沢市泉野町4−12−5−401 Fターム(参考) 4B018 LE03 MD82 ME08 MF01 MF04 MF06 4C088 AA07 AC16 AC17 BA05 BA23 BA24 CA02 CA14 CA16 MA52 NA11 NA14 ZB26  ──────────────────────────────────────────────────続 き Continuation of the front page (72) Inventor Tomohisa Ota 2-28-60 Heiwacho, Kanazawa-shi, Ishikawa (72) Inventor Takuma Sasaki 4-12-5-401 Izunocho, Kanazawa-shi, Ishikawa F-term (reference) 4B018 LE03 MD82 ME08 MF01 MF04 MF06 4C088 AA07 AC16 AC17 BA05 BA23 BA24 CA02 CA14 CA16 MA52 NA11 NA14 ZB26

Claims (2)

【特許請求の範囲】[Claims] 【請求項1】 カワリハラタケの子実体を熱水抽出する
工程、抽出液を透析処理する工程、得られる透析外液を
クロマトグラフィー処理する工程、得られる分子量10
0〜2000のクロマトグラフィー主溶出画分を有効成
分とする抗腫瘍剤もしくは健康食品。
1. A step of extracting the fruit body of Kawariharatake with hot water, a step of dialysis of the extract, a step of chromatography of the obtained outer dialysis solution, and a molecular weight of 10
An antitumor agent or health food comprising a chromatographic main elution fraction of 0 to 2000 as an active ingredient.
【請求項2】 カワリハラタケの子実体を熱水抽出する
工程、抽出物にエタノールを加えて混合し、混合物を遠
心分離して沈殿と上澄液に分ける工程、上澄液にエタノ
ールを加えて混合し、混合物を遠心分離して沈殿と上澄
液に分ける工程、沈殿物を蒸留水に溶解して透析処理す
る工程、得られる透析外液を有効成分とする抗腫瘍剤も
しくは健康食品。
2. A step of extracting the fruit body of Kawariharatake with hot water, a step of adding and mixing ethanol to the extract, a step of separating the mixture by centrifugation into a precipitate and a supernatant, and adding and mixing ethanol to the supernatant. And separating the mixture into a precipitate and a supernatant by centrifugation, dissolving the precipitate in distilled water for dialysis, and an antitumor agent or health food containing the obtained dialysate as an active ingredient.
JP18811299A 1999-07-01 1999-07-01 Anti-tumor fraction of Kawariharatake Expired - Lifetime JP4480204B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP18811299A JP4480204B2 (en) 1999-07-01 1999-07-01 Anti-tumor fraction of Kawariharatake

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP18811299A JP4480204B2 (en) 1999-07-01 1999-07-01 Anti-tumor fraction of Kawariharatake

Publications (2)

Publication Number Publication Date
JP2001010970A true JP2001010970A (en) 2001-01-16
JP4480204B2 JP4480204B2 (en) 2010-06-16

Family

ID=16217923

Family Applications (1)

Application Number Title Priority Date Filing Date
JP18811299A Expired - Lifetime JP4480204B2 (en) 1999-07-01 1999-07-01 Anti-tumor fraction of Kawariharatake

Country Status (1)

Country Link
JP (1) JP4480204B2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004004748A1 (en) * 2002-07-02 2004-01-15 Kyowa Engineering Co., Ltd. Agaricus blazei murill extract capable of preventing cancer induction or metastasis
WO2004073727A1 (en) * 2003-02-19 2004-09-02 Sundory Co., Ltd. Method for improving qol and composition therefor
JP2005035928A (en) * 2003-07-14 2005-02-10 Kobayashi Pharmaceut Co Ltd Fractionated product of cordyceps sinensis mycelium extract, and composition for oral administration
WO2005027952A1 (en) * 2003-09-17 2005-03-31 Ssi Co., Ltd Composition exerting physiological activity via biological immune mechanism

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004004748A1 (en) * 2002-07-02 2004-01-15 Kyowa Engineering Co., Ltd. Agaricus blazei murill extract capable of preventing cancer induction or metastasis
JPWO2004004748A1 (en) * 2002-07-02 2005-11-04 協和エンジニアリング株式会社 Kawariharatake extract prevents cancer induction or cancer metastasis
US7611715B2 (en) 2002-07-02 2009-11-03 Ssi Co., Ltd. Agaricus extract for preventing the induction or metastasis of cancer
KR101035262B1 (en) 2002-07-02 2011-05-18 카부시키카이샤 에스·에스·아이 Agaricus extract for preventing the induction or metastasis of cancer
JP4823519B2 (en) * 2002-07-02 2011-11-24 協和発酵バイオ株式会社 Kawariharatake extract prevents cancer induction or cancer metastasis
WO2004073727A1 (en) * 2003-02-19 2004-09-02 Sundory Co., Ltd. Method for improving qol and composition therefor
JP2005035928A (en) * 2003-07-14 2005-02-10 Kobayashi Pharmaceut Co Ltd Fractionated product of cordyceps sinensis mycelium extract, and composition for oral administration
JP4746260B2 (en) * 2003-07-14 2011-08-10 小林製薬株式会社 Fractionated Cordyceps mycelium extract and composition for oral consumption
WO2005027952A1 (en) * 2003-09-17 2005-03-31 Ssi Co., Ltd Composition exerting physiological activity via biological immune mechanism
JPWO2005027952A1 (en) * 2003-09-17 2006-11-24 株式会社S・S・I Composition that expresses physiological activity through immune mechanism of living body

Also Published As

Publication number Publication date
JP4480204B2 (en) 2010-06-16

Similar Documents

Publication Publication Date Title
WO2001051070A1 (en) Physiologically active substance eem-s originating in mushrooms, process for producing the same and drugs
JPH02111725A (en) Drug composition
JPS62209101A (en) Immuno-stimulative polysaccharides from cell culture of echinacea prupurea or echinacea angustifolia, its production and preparation containing the same
CN109608557A (en) Polysaccharides extracts Isolation and purification method, Lycium chinense glycopeptide and preparation method
CN103539831A (en) Prunus armeniaca alpha-glucosidase inhibiting peptide as well as preparation method and application of inhibiting peptide
CN103539833A (en) High-activity alpha-glucosidase inhibitory peptide and preparation method and application thereof
JPH11503453A (en) Mistletoe extract and method
JP2001010970A (en) Antineoplastic fraction from agaricus blazei murill
EP1002541A1 (en) Oral drugs for amelioration of aids symptoms
JP3051073B2 (en) Antitumor active substance
WO2009136805A1 (en) Immunostimulating agent and a method for the production thereof
JPH11152230A (en) Composition containing mushroom or its extract
JP2000226330A (en) Water-soluble echinacea and its production
JP2004059558A (en) Method for collecting physiologically active substance from fungus, preparation of physiologically active substance of the same and use of the same
JPH11302191A (en) Immunoactivator and antitumor agent containing extract from lyophyllum decastes (fr.) sing. as active ingredient
JP2001064195A (en) Collection of physiologically active substance from mushrooms and/or yeasts, and the physiologically active substance
CN116874627B (en) Stemona tuberosa polysaccharide and preparation method and application thereof
JP7479538B1 (en) Carob polysaccharides with antihypertensive effect, their production method and use
CN114230646B (en) Antitumor grifola frondosa glycoprotein and preparation method and application thereof
CN109305994B (en) Pure powder of ground beetle dry powder enzymolysis, preparation and application thereof
CN108514576B (en) Folium Mori extract prepared by ultrasonic extraction technology and its application
CN108250258B (en) New flavone glycoside prepared by fermentation and ultrasonic extraction technology
JPH0379602A (en) Polysaccarhide having immno- stimulation/anti-proliferation effect, its manufacture and drug containing said material
CN113491762A (en) Medicine for medical application of heart
JP4165690B2 (en) Method for producing interleukin 12 production promoting composition

Legal Events

Date Code Title Description
A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 19990728

A80 Written request to apply exceptions to lack of novelty of invention

Free format text: JAPANESE INTERMEDIATE CODE: A80

Effective date: 19990728

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20030908

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20031121

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20051118

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20051118

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060127

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20060127

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070904

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071102

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20090518

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20090520

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090525

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090611

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090717

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091215

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100209

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100309

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100316

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130326

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4480204

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313117

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130326

Year of fee payment: 3

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140326

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term